Nuvectis Pharma (NVCT)

Executive Summary

Nuvectis Pharma is a clinical-stage biopharmaceutical company developing novel targeted cancer therapies. Its lead candidate, NXP800, is an oral small molecule inhibitor of the HSF1 pathway, a key regulator of the stress response in cancer cells. NXP800 is in a Phase 1 trial for advanced solid tumors, with a focus on ovarian clear cell carcinoma and ARID1A-mutated tumors. The trial has completed enrollment and initial data are expected. The second candidate, NXP900, is a Src/Yes1 inhibitor being evaluated as monotherapy in advanced solid tumors and in combination with osimertinib for EGFR-mutant non-small cell lung cancer (NSCLC). Both programs are in early clinical development, with safety and efficacy data awaited. Nuvectis has a focused pipeline targeting high-unmet-need cancers with novel mechanisms. The company is publicly traded (NVCT) and has a market valuation of approximately $265 million. Key upcoming milestones include data readouts from the NXP800 Phase 1 trial and initial results from the NXP900 monotherapy and combination studies.

Upcoming Catalysts (preview)

• Q2 2026NXP800 Phase 1 data readout in advanced solid tumors40% success
• H2 2026NXP900 monotherapy Phase 1 initial safety and efficacy data35% success
• H1 2027NXP900 + osimertinib Phase 1 dose-escalation data in EGFR-mutant NSCLC30% success